Newborn Screening

Prof Alessandra Ferlini presents on Screen4Care at ESHG 2024

Prof Alessandra Ferlini presents on Screen4Care at ESHG 2024

As Scientific Coordinator for Screen4Care, a major public-private consortium focused on evaluating the potential of next-generation sequencing and digital tools for newborn screening in Europe, Prof Alessandra Ferlini plays a leading role in an important research initiative that aims to drive early detection and proactive treatment of serious genetic disorders. In this recent presentation at a […]

Prof Alessandra Ferlini presents on Screen4Care at ESHG 2024 Read More »

Improving rare disease diagnostics in Korea: spotlight on Prof Jong-Hee Chae

Improving rare disease diagnostics in Korea: spotlight on Prof Jong-Hee Chae

Widely recognised as one of Korea’s top experts in rare genetic diseases, Prof Jong-Hee Chae serves as Professor in the Department of Clinical Genomic Medicine and Director of the Rare Disease Centre at Seoul National University Hospital (SNUH), one of the country’s leading academic medical institutions. Among her many responsibilities, Prof Chae plays a key

Improving rare disease diagnostics in Korea: spotlight on Prof Jong-Hee Chae Read More »

Screen4Care, NGS and newborn screening in Europe: Q&A with Prof Alessandra Ferlini and Enrico Bertini

Screen4Care, NGS and newborn screening in Europe: Q&A with Drs Alessandra Ferlini and Enrico Bertini

Launched in 2021 via a major public-private consortium in Europe, Screen4Care is a 5-year research project to evaluate the potential of next-generation sequencing (NGS) and digital tools to improve newborn screening (NBS) systems, accelerate the diagnosis of rare genetic diseases, and ultimately link patients with treatments or interventions that can drive better health outcomes. After

Screen4Care, NGS and newborn screening in Europe: Q&A with Prof Alessandra Ferlini and Enrico Bertini Read More »

How Taiwan screens newborns for Duchenne muscular dystrophy

How Taiwan screens newborns for Duchenne muscular dystrophy_thumbnail

Taiwan is one of only a small group of countries and territories around the world that routinely screens most newborns for Duchenne muscular dystrophy (DMD), a serious genetic disease that primarily affects boys. Amid ongoing advances in the scientific understanding and treatment of DMD, however, more countries are likely to consider adding the condition to their

How Taiwan screens newborns for Duchenne muscular dystrophy Read More »

BabySeq, ICoNS and the power of newborn sequencing: Q&A with Dr Robert Green

BabySeq, ICoNS and the power of newborn sequencing: Q&A with Dr Robert Green

Dr Robert Green is a physician-scientist who has spent much of his career at the forefront of the exciting field of translational genomics. In this Q&A with Will Greene, Healthcare Engagement Lead at Roche Diagnostics Asia Pacific, Dr Green talks about his pioneering work in newborn sequencing, including via the BabySeq project and the International

BabySeq, ICoNS and the power of newborn sequencing: Q&A with Dr Robert Green Read More »

Exome sequencing improves rare disease diagnostics in Taiwan

Exome sequencing improves rare disease diagnostics in Taiwan

With ongoing advances in next-generation sequencing (NGS) technology, clinical geneticists and researchers around the world are exploring the role of whole exome sequencing for rare disease diagnostics. In the Asia Pacific region, Taiwan is emerging as a leader in the use of exome sequencing for both research and clinical applications. Compared to single gene or

Exome sequencing improves rare disease diagnostics in Taiwan Read More »

Genomic newborn screening and the BeginNGS project: Q&A with Dr Stephen Kingsmore (Part 2)

kingsmore thumb 2

Rady Children’s Institute for Genomic Medicine (RCIGM) is widely regarded as a key player in the global ecosystem of research groups that are exploring the role of whole genome sequencing for newborn screening. In this Q&A with Will Greene, Healthcare Engagement Lead for Roche Diagnostics Asia Pacific, RCIGM President & CEO Dr Stephen Kingsmore provides

Genomic newborn screening and the BeginNGS project: Q&A with Dr Stephen Kingsmore (Part 2) Read More »

Diagnostic whole genome sequencing for rare diseases: Q&A with Dr Stephen Kingsmore (Part 1)

kingsmore part 1 thumb

As President & CEO of Rady Children’s Institute for Genomic Medicine, Dr Stephen Kingsmore plays a key role in driving access to diagnostic whole genome sequencing (WGS) services for children with symptoms of genetic disease. In this Q&A with Will Greene, Healthcare Engagement Lead for Roche Diagnostics Asia Pacific, Dr Kingsmore discusses how the institute provides

Diagnostic whole genome sequencing for rare diseases: Q&A with Dr Stephen Kingsmore (Part 1) Read More »

Newborn screening for SMA: Australia’s Dr Michelle Farrar on why ‘every day counts’

Newborn screening for SMA in Australia: Q&A with Dr Michelle Farrar

A paediatric neurologist and clinical academic researcher with deep experience in spinal muscular atrophy (SMA), Dr Michelle Farrar played a central role in Australia’s efforts to add SMA to newborn screening panels. In this Q&A for Lab Insights, Dr Farrar discusses the process of piloting and launching SMA testing for newborns.  “What we learned is

Newborn screening for SMA: Australia’s Dr Michelle Farrar on why ‘every day counts’ Read More »

Newborn screening innovation ramps up at Murdoch Children’s in Australia

Newborn screening innovation ramps up at Murdoch Children’s Australia

  As interest and investment in newborn bloodspot screening (NBS) grows across Australia, the Murdoch Children’s Research Institute in Melbourne is gaining momentum as an important centre for NBS research and innovation in the country. Based at the Royal Children’s Hospital in Melbourne, the capital of the State of Victoria in south-eastern Australia, Murdoch Children’s

Newborn screening innovation ramps up at Murdoch Children’s in Australia Read More »

Scroll to Top